Profile data is unavailable for this security.
About the company
Sirnaomics Ltd. is an investment holding company. The Company and its subsidiaries are clinical-stage biotechnology companies that are engaged in developing and commercializing ribonucleic acid interference (RNAi) technology and multiple therapeutics. The Company is engaged in discovering and developing drugs for indications with unmet medical needs in areas. Its lead clinical drug candidates include STP705 and STP707. Its STP705 is a sterile drug product for the treatment of nonmelanoma skin cancer (NMSC), including squamous cell carcinoma in situ and basal cell carcinoma (BCC), recurrent keloids after keloidectomy, hypertrophic scar (HTS) and solid liver tumors, as well as for medical aesthetics. Its STP707 is a sterile drug product for the treatment of solid tumors, including liver cancer, metastatic cutaneous squamous-cell skin cancer (cSCC) and non-small cell lung cancer. It is capitalizing on its dual delivery platforms, which include Polypeptide nanoparticle (PNP) and GalAhead.
- Revenue in HKD (TTM)0.00
- Net income in HKD-615.64m
- Incorporated2007
- Employees145.00
- LocationSirnaomics Ltd401 Professional Drive, Suite 280GAITHERSBURG 20879United StatesUSA
- Websitehttps://www.sirnaomics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hin Sang Group (Interntnl) Hldng Co Ltd | 92.79m | -35.72m | 327.54m | 265.00 | -- | 1.49 | -- | 3.53 | -0.0327 | -0.0327 | 0.085 | 0.202 | 0.1524 | 2.29 | 9.49 | 366,766.80 | -5.81 | -4.06 | -8.74 | -5.26 | 55.95 | 61.98 | -38.14 | -20.98 | 0.1129 | -1.15 | 0.5766 | -- | -32.42 | -15.45 | -315.54 | -- | -36.30 | -- |
| Kintor Pharmaceutical Ltd | 0.00 | -1.15bn | 415.64m | 225.00 | -- | 0.8396 | -- | -- | -2.67 | -2.67 | 0.00 | 1.11 | 0.00 | 0.14 | -- | 0.00 | -72.55 | -50.15 | -89.09 | -58.43 | -- | -23.36 | -- | -10,511.41 | 2.10 | -- | 0.3566 | -- | -- | -- | -11.15 | -- | -- | -- |
| Clover Biopharmaceuticals Ltd | 42.42m | -149.70m | 446.89m | 387.00 | -- | -- | -- | 10.54 | -0.1199 | -0.1199 | 0.034 | -0.6109 | 0.0116 | 0.0098 | 0.7449 | 109,607.60 | -4.08 | -- | -16.40 | -- | 61.75 | -- | -352.92 | -- | 0.5281 | -1.45 | -- | -- | -- | -- | 94.35 | -- | -- | -- |
| Uni-Bio Science Group Ltd | 484.72m | 70.88m | 511.58m | 407.00 | 7.45 | 2.05 | 5.83 | 1.06 | 0.0111 | 0.0111 | 0.0762 | 0.0404 | 1.38 | 2.62 | 9.44 | 1,190,953.00 | 20.18 | 1.46 | 28.50 | 1.97 | 81.04 | 80.59 | 14.62 | 1.23 | 1.76 | 97.93 | 0.1796 | -- | 10.08 | 29.08 | 84.04 | -- | -- | -- |
| Tianda Pharmaceuticals Ltd | 532.09m | -24.16m | 559.01m | 863.00 | -- | 0.9442 | 43.92 | 1.05 | -0.0112 | -0.0112 | 0.2475 | 0.2754 | 0.5306 | 4.88 | 4.37 | 616,557.40 | -2.49 | -- | -3.84 | -- | 48.02 | -- | -4.70 | -- | 0.8907 | -10.16 | 0.161 | -- | -- | -- | -- | -- | -- | -- |
| Sirnaomics Ltd | 0.00 | -615.64m | 602.87m | 145.00 | -- | 1.92 | -- | -- | -8.10 | -8.10 | 0.00 | 3.59 | 0.00 | -- | -- | 0.00 | -70.91 | -- | -71.22 | -- | -- | -- | -- | -- | -- | -- | 0.6176 | -- | -- | -- | 10.88 | -- | -- | -- |
| Genor Biopharma Holdings Ltd | 0.00 | -728.70m | 639.84m | 104.00 | -- | 0.4932 | -- | -- | -1.44 | -1.44 | 0.00 | 2.53 | 0.00 | 0.00 | -- | 0.00 | -37.91 | -55.46 | -44.02 | -63.73 | -- | 66.56 | -- | -14,819.18 | 5.38 | -- | 0.006 | -- | -100.00 | -- | 7.65 | -- | -- | -- |
| Pak Fah Yeow International Ltd | 259.16m | 105.04m | 651.33m | 102.00 | 6.20 | 0.8512 | 5.79 | 2.51 | 0.337 | 0.337 | 0.8316 | 2.46 | 0.2995 | 2.88 | 22.18 | 2,540,765.00 | 12.14 | 3.99 | 12.60 | 4.18 | 84.45 | 80.79 | 40.53 | 21.27 | 6.90 | 10.08 | 0.0062 | 100.68 | 76.06 | 12.94 | 250.66 | 23.02 | 18.83 | -8.06 |
| Lee's Pharmaceutical Holdings Ltd | 1.05bn | 16.70m | 653.61m | 1.06k | 39.14 | 0.3206 | 3.86 | 0.6207 | 0.0284 | 0.0284 | 1.79 | 3.46 | 0.3713 | 1.83 | 10.75 | 996,247.90 | 0.7033 | 13.33 | 0.88 | 17.76 | 52.35 | 61.92 | 1.89 | 36.20 | 0.5526 | 3.90 | 0.0943 | 3.59 | -14.61 | -1.53 | -67.44 | -47.49 | -12.19 | -31.34 |
| Fusen Pharmaceutical Co Ltd | 611.18m | -39.20m | 666.60m | 1.15k | -- | 1.09 | 18.53 | 1.09 | -0.0525 | -0.0525 | 0.8127 | 0.8123 | 0.4199 | 1.95 | 4.47 | 532,390.40 | -2.69 | 0.9678 | -5.54 | 1.74 | 52.95 | 51.95 | -6.42 | 2.59 | 0.6096 | 0.71 | 0.3797 | -- | 15.02 | 4.13 | -4.83 | -- | -- | -- |
| Antengene Corporation Ltd | 72.73m | -628.01m | 687.50m | 201.00 | -- | 0.5545 | -- | 9.45 | -1.02 | -1.02 | 0.1182 | 1.84 | 0.0358 | 0.9773 | 3.41 | 361,832.70 | -30.91 | -53.57 | -36.46 | -58.94 | 81.74 | -- | -863.51 | -1,987.01 | 6.43 | -- | 0.1491 | -- | -57.97 | -- | 3.38 | -- | -- | -- |
| Jbm (Healthcare) Ltd | 610.30m | 97.99m | 725.41m | 258.00 | 8.01 | 0.7735 | 4.88 | 1.19 | 0.1087 | 0.1087 | 0.6786 | 1.12 | 0.4406 | 5.88 | 4.10 | 2,000,994.00 | 7.56 | 3.33 | 9.04 | 4.93 | 47.70 | 45.97 | 17.17 | 10.97 | 1.45 | 22.15 | 0.1211 | 13.81 | 28.11 | 14.51 | 131.90 | 6.14 | -5.09 | -- |
| JW (Cayman) Therapeutics Co Ltd | 187.87m | -829.88m | 740.75m | 398.00 | -- | 0.4052 | -- | 3.94 | -2.02 | -2.02 | 0.4565 | 4.41 | 0.0704 | 1.68 | 65.54 | 472,023.00 | -31.11 | -39.77 | -35.21 | -44.00 | 50.74 | -- | -441.74 | -1,316.81 | 3.86 | -47.82 | 0.1592 | -- | 19.32 | -- | 9.23 | -- | -19.87 | -- |
| Transcenta Holding Limited | 58.19m | -499.84m | 788.82m | 215.00 | -- | 0.7085 | -- | 13.56 | -1.23 | -1.23 | 0.143 | 2.55 | 0.0281 | 2.05 | 1.49 | 270,642.30 | -24.17 | -- | -33.97 | -- | 26.74 | -- | -859.01 | -- | 1.20 | -32.87 | 0.285 | -- | -47.15 | -- | -13.72 | -- | -- | -- |
| Zhaoke Ophthalmology Ltd | 20.26m | -416.06m | 856.34m | 313.00 | -- | 0.3869 | -- | 42.27 | -0.765 | -0.765 | 0.0373 | 4.05 | 0.0075 | -- | 0.3433 | 64,731.17 | -15.43 | -- | -17.27 | -- | 75.98 | -- | -2,053.54 | -- | 5.32 | -47.54 | 0.1041 | -- | -- | -- | 5.47 | -- | -- | -- |
Data as of May 02 2024. Currency figures normalised to Sirnaomics Ltd's reporting currency: Hong Kong Dollar HKD
4.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 Apr 2024 | 2.35m | 2.68% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 657.30k | 0.75% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2022 | 633.45k | 0.72% |
| Charles Schwab Investment Management, Inc.as of 04 Apr 2024 | 138.47k | 0.16% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 84.10k | 0.10% |
| Vanguard Global Advisers LLCas of 31 Mar 2024 | 20.40k | 0.02% |
| E Fund Management Co., Ltd.as of 30 Jun 2023 | 2.65k | 0.00% |
| China Asset Management Co., Ltd.as of 30 Jun 2023 | 0.00 | 0.00% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2023 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2023 - 22 Apr 2024Source: FactSet Research Systems Inc.
